IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stake Reduced by Federated Hermes Inc.

Federated Hermes Inc. decreased its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 2.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,063,526 shares of the company’s stock after selling 144,774 shares during the period. Federated Hermes Inc. owned approximately 0.06% of IDEAYA Biosciences worth $130,133,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Trexquant Investment LP bought a new stake in IDEAYA Biosciences during the fourth quarter worth approximately $2,754,000. Geode Capital Management LLC boosted its stake in shares of IDEAYA Biosciences by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company’s stock worth $51,121,000 after acquiring an additional 43,226 shares in the last quarter. B. Metzler seel. Sohn & Co. AG acquired a new position in shares of IDEAYA Biosciences in the 4th quarter worth $701,000. Pictet Asset Management Holding SA grew its holdings in shares of IDEAYA Biosciences by 2.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,941,271 shares of the company’s stock worth $49,891,000 after acquiring an additional 46,931 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of IDEAYA Biosciences during the fourth quarter worth $13,385,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Down 5.5 %

IDYA stock opened at $14.71 on Friday. The company has a 50 day moving average of $20.05 and a two-hundred day moving average of $25.11. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -4.46 and a beta of 0.51. IDEAYA Biosciences, Inc. has a 12-month low of $14.40 and a 12-month high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.00 million. On average, research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on IDYA. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Stephens reiterated an “overweight” rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday, February 14th. Wedbush restated an “outperform” rating and set a $52.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, IDEAYA Biosciences has an average rating of “Moderate Buy” and an average price target of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.